Financial Data and Key Metrics Changes - Total revenue for Q2 2025 was $625,000, representing a 36% increase year-over-year and a 29% sequential increase [19] - EVOLVE sales increased by 94% year-over-year and accounted for 83% of total revenue, while ContraPest sales decreased by approximately 45% [19] - Gross profit margins improved to 65.4%, up from 54.2% in the same quarter last year and 64.5% sequentially [22] Business Line Data and Key Metrics Changes - EVOLVE now constitutes 83% of total quarterly revenue, with gross profit dollars up 64% compared to last year's Q2 [6][22] - E-commerce sales grew by 78% year-over-year and accounted for over 50% of quarterly sales, with Amazon leading the channel [8][20] - Municipal sales saw a 538% increase year-over-year, driven by deployments in cities like Chicago and New York [21] Market Data and Key Metrics Changes - E-commerce sales were up 78% compared to last year and up 18% sequentially, with significant growth in brick-and-mortar retail sales, which increased nearly 500% sequentially [8][21] - International sales included a follow-on order from the Caribbean, with ongoing regulatory approvals in Australia and New Zealand [12][21] Company Strategy and Development Direction - The company is focused on expanding its market presence through the EVOLVE product line, which has opened new verticals and distribution channels [5][16] - Plans are in place to accelerate e-commerce growth and expand into agricultural applications, where significant opportunities exist [32][14] - The company aims to achieve cash flow breakeven at approximately $1,500,000 in quarterly revenue, with expectations for growth in 2026 [25][39] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in continued growth from city and government trials, anticipating increased orders as results from trials prove successful [33] - The company is optimistic about its position in the market, citing a large addressable global market and regulatory tailwinds [28] - Management highlighted the importance of focusing on the EVOLVE product line to maximize market penetration and operational efficiency [49] Other Important Information - The company ended the quarter with $6,100,000 in cash, following successful financing activities [26] - The new manufacturing facility has the capacity to produce approximately $10,000,000 in revenue, with plans for further expansion [34] Q&A Session Summary Question: Should we expect incremental improvements to gross margins in the coming quarters? - Yes, management expects margins to remain consistent and possibly improve [30] Question: Is there room to accelerate e-commerce growth with additional digital marketing spend? - Yes, plans are in place to accelerate growth across all channels [31] Question: Should we expect higher volumes from cities where the product has been launched? - Yes, as trials prove successful, increased orders and revenues are anticipated [33] Question: What is the potential capacity in terms of dollars of the expanded manufacturing facility? - The facility can produce roughly $10,000,000 in revenue with current operations [34] Question: Are you planning to do more capital raises in the future? - No further financings are anticipated in the near future, as the company has sufficient cash to reach cash flow profitability [36] Question: Would a full-scale New York City expansion require a big capital investment? - No significant capital investment is required immediately, but future expansions may need some capital [38] Question: Do you need to hire additional people to meet growth expectations? - Yes, the company is hiring salespeople and expanding its field team to support growth [40] Question: Are there any active trials that have not been announced? - Yes, there are ongoing trials that have not yet been disclosed [42] Question: How long before you are in store with Tractor Supply? - The company hopes to have news on this in the coming months [46] Question: Can you specify how OpEx will be cut? - Cuts have already been made, and there are no specific plans for further reductions at this time [47]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number: 001-37941 SENESTECH, INC. (Exact name of registrant as specified in its charter) | Delaware | 20-2079805 | ...

Balance Sheet Highlights • Current cash balance as of August 5, 2025 is $11.2 million — This provides us with an operating runway through the end of 2027 and beyond, based on the most recent quarterly run rate. Exhibit 99.1 SenesTech Reports Second Quarter 2025 Financial Results with Record Revenue and Record Gross Profit Margins 94% Revenue Growth in Evolve Rodent Birth Control Products TM Strong Cash Balance and Sustained Progress Toward Profitability SURPRISE, Ariz., August 7, 2025 /PRNewswire/ — SenesTe ...

Core Viewpoint - SenesTech, Inc. has successfully closed the exercise of outstanding warrants, raising approximately $6.3 million, and issued new short-term warrants for additional capital [1][4]. Group 1: Financial Details - The company exercised warrants to purchase 1,458,872 shares at an exercise price of $4.15 per share [1]. - New unregistered short-term warrants were issued to purchase up to 2,188,308 shares at an exercise price of $5.25 per share, with a purchase price of $0.125 per warrant [3]. - The potential gross proceeds from the new short-term warrants, if fully exercised, could amount to approximately $11.5 million [4]. Group 2: Use of Proceeds - The net proceeds from the transaction are expected to be used for working capital and general corporate purposes [4]. Group 3: Company Overview - SenesTech is focused on humane management of animal pest populations through fertility control, with products like ContraPest® and Evolve™ [8]. - ContraPest® is the only U.S. EPA-registered contraceptive for male and female rats, while Evolve™ products are designated as minimum risk contraceptives for rodents [8].

Core Points - SenesTech, Inc. announced the closing of the exercise of outstanding warrants to purchase 1,458,872 shares of common stock at an exercise price of $2.90 per share, generating approximately $4.4 million in gross proceeds [1][4] - The company issued new unregistered short-term warrants for the same number of shares at an exercise price of $4.15 per share, with a purchase price of $0.125 per warrant, potentially raising an additional $6.0 million if fully exercised [3][4] - The net proceeds from the transaction are intended for working capital and general corporate purposes [4] Company Overview - SenesTech is focused on humane management of animal pest populations through fertility control, having developed products like ContraPest®, the only U.S. EPA-registered contraceptive for rats, and Evolve™ products for rodents [8]

Core Viewpoint - SenesTech, Inc. has entered into definitive agreements for the immediate exercise of outstanding warrants to purchase 1,458,872 shares of common stock at an exercise price of $2.90 per share, with the transaction expected to close around July 1, 2025 [1] Group 1: Warrant Exercise and Financial Details - The company will issue new unregistered short-term warrants to purchase an additional 1,458,872 shares at an exercise price of $4.15 per share, with a purchase price of $0.125 per warrant [3] - The gross proceeds from the exercise of existing warrants are expected to be approximately $4.4 million, while potential gross proceeds from the new short-term warrants could reach approximately $6.0 million if fully exercised [4] - The net proceeds from the transaction are intended for working capital and general corporate purposes [4] Group 2: Regulatory and Compliance Information - The resale of shares from the existing warrants has been registered under an effective registration statement on Form S-3 [5] - The new short-term warrants have not been registered under the Securities Act of 1933, and may not be offered or sold in the U.S. without an effective registration statement or applicable exemption [6] Group 3: Company Overview - SenesTech is focused on humane management of animal pest populations through fertility control, with products like ContraPest® and Evolve™ designed for effective pest management [8]

Core Insights - SenesTech, Inc. has reported successful results from urban deployments of its Evolve™ Rat Birth Control in Hong Kong and San Francisco, demonstrating a faster and more sustainable approach to rodent control by combining fertility control with traditional rodenticides [1][3][5] Group 1: Urban Rodent Challenges - Global cities are facing persistent rodent issues due to dense infrastructure, hard-to-access breeding sites, and abundant food sources, leading to the inadequacy of traditional rodenticide programs over time [2] - Rodents have shown adaptability to poisons, resulting in unchecked reproduction despite aggressive control measures [2] Group 2: Integrated Pest Management Strategy - The integrated strategy employed in Hong Kong involved deploying Evolve's palatable soft bait alongside conventional rodenticide blocks, leading to a significant reduction in rodent sightings and no new litters detected within three months [3][4] - In San Francisco, a similar approach resulted in reduced visible rodent activity, decreased overall poison usage, and a measurable drop in new rodent births [4] Group 3: Industry Implications - The success of these deployments indicates that fertility control can serve as a practical tool for pest professionals, enhancing integrated pest management (IPM) programs and reducing reliance on rodenticides [5] - The company is preparing for a container-sized order from Hong Kong, signaling rapid expansion and increased demand for its products [5] Group 4: Market Opportunities - Fertility control solutions like Evolve align with evolving environmental regulations and public demand for humane, low-toxicity pest management, offering improved outcomes and better ROI for pest control professionals and property owners [6] - This trend indicates a rapidly growing global market for next-generation rodent control solutions that complement traditional methods [6]

Core Insights - SenesTech, Inc. has successfully completed a nine-month field trial of its Evolve™ Rat Birth Control at the University Hills community, marking a significant step in ecologically responsible pest management [1][2][3] - The initiative, driven by resident demand, aimed to eliminate rodenticides in favor of integrated pest management strategies that prioritize environmental safety [2][5] - Evolve was deployed across 267 bait stations, achieving a 98% consumption rate among rats, indicating high acceptance and effectiveness of the bait [3][5] Company Overview - SenesTech specializes in fertility control solutions for managing animal pest populations, with products like ContraPest® and Evolve™ designed to be humane, effective, and sustainable [7] - The company emphasizes its commitment to improving global health through responsible pest management practices [7] Community Engagement - The project involved collaboration with the Irvine Campus Housing Authority and the grassroots initiative HOOT Group, which promotes owl nesting to reduce reliance on rodenticides [4][5] - The community's transition away from rodenticides has led to reduced rodent complaints and less observed rodent activity [5] Future Plans - SenesTech is placing a multi-pallet restocking order for continued deployment and expansion of its products [6]

Core Insights - SenesTech has entered a distribution agreement with Bradley Caldwell, Inc. to enhance the availability of Evolve™ Rodent Birth Control in rural America [1][2] - The partnership aims to leverage BCI's extensive network of over 8,000 dealers to improve access to rodent control solutions in agricultural communities [1][2] - This agreement represents a significant step in SenesTech's commercialization strategy, with BCI's initial order being the largest distributor stocking order received by the company [3] Company Overview - SenesTech specializes in fertility control for managing animal pest populations, with products like ContraPest and Evolve designed to be humane and effective [4] - The company focuses on providing sustainable pest management solutions that integrate into existing pest management programs [4] Strategic Benefits - The partnership with BCI is expected to accelerate market penetration in underserved areas where traditional rodenticides face challenges [7] - BCI customers will gain a competitive edge by offering a scientifically-backed, humane alternative to traditional poisons [7] - The collaboration supports SenesTech's long-term growth strategy, anticipating revenue increases from expanded retail sales and new customer acquisition [7]

Summary of SenesTech (SNES) 2025 Conference Call Company Overview - **Company**: SenesTech, a biotech and life sciences company focused on rodent control through reproductive management rather than lethal methods [5][6] - **Ticker Symbol**: SNES, traded on NASDAQ [4] Core Product and Market Strategy - **Flagship Product**: Evolve, launched in 2024, is a soft bait designed for rodent fertility control, which has quickly become the top-selling product [12][14] - **Sales Growth**: Evolve sales grew by 40% year-over-year in Q1 2025 [15][37] - **Market Opportunity**: The U.S. rodenticide market is estimated at $1 billion annually, with a global market of $4.5 billion [34] Unique Selling Proposition - **Sustainable Approach**: Focus on controlling the birth rate of rodents rather than relying on poisons, which have social, political, and ecological drawbacks [6][8][30] - **Product Safety**: Evolve is designated as a minimum risk product by the EPA, using cottonseed oil as the active ingredient, making it safer for pets and wildlife [14][16] Distribution Channels - **Six Channel Strategy**: Includes e-commerce, agriculture distributors, pest management distributors, retail (e.g., Ace Hardware), international distributors, and direct sales to large customers [18][19] - **E-commerce Growth**: E-commerce sales increased by over 7%, with a run rate approaching $60,000 to $70,000 per month [20][21] Municipal and International Opportunities - **Municipal Deployments**: Significant projects in Chicago and New York City, with repeat orders indicating product effectiveness [23][24][25] - **International Expansion**: Exclusive distribution agreements signed in 12 countries, with expected approvals in Australia and New Zealand [27][28] Financial Performance - **Revenue Growth**: Record revenue of $1.9 million in 2024, up 56% from the previous year [39] - **Gross Margin Improvement**: Gross margins for Evolve reached 64%, compared to 32% in Q1 of the previous year [40] - **Cost Optimization**: Initiatives to reduce operating costs include pausing new product development and optimizing sales efforts [44] Future Outlook - **Path to Profitability**: Aiming for cash flow breakeven at approximately $1.5 million per quarter, with current revenues around $500,000 per quarter [45][46] - **Market Trends**: Increasing awareness of the need for humane rodent control solutions due to public health concerns and regulatory changes [52][53] Key Takeaways - **Transformative Opportunity**: SenesTech believes it has a paradigm-changing product that addresses long-standing rodent control issues in a sustainable manner [55][56] - **Execution Strategy**: Focus on expanding market presence, improving product offerings, and enhancing operational efficiencies to drive future growth [54][56]